Effects of Active Hexose Correlated Compound (AHCC®) on Clinical and Laboratory Response of Pulmonary Tuberculosis Patients
DOI:
https://doi.org/10.36497/jri.v45i4.820Keywords:
AHCC, clinical symptoms, hematology, immunology, tuberculosisAbstract
Backgrounds: Active hexose correlated compound (AHCC), an α-glucan extracted from Lentinula edodes, is known for its immunomodulatory properties. It is suspected that the strong nutrients contained in AHCC are very safe and without side effects, including in tuberculosis patients. This study evaluated the effect of AHCC on clinical and hematologic responses in pulmonary tuberculosis (TB) patients
Methods: A double-blind randomized controlled trial was conducted involving 60 pulmonary TB patients receiving standard anti-TB therapy. Participants were randomly assigned to receive either AHCC (3 g/day) or a placebo for six months. Clinical and laboratory parameters were assessed before and after treatment.
Results: Patients in the AHCC group showed greater improvement in clinical symptoms (reduced cough, improved appetite, and weight gain) and significant enhancement of hematological and immunological markers compared with placebo (P<0.05). AHCC supplementation significantly increased CD4⁺ and CD8⁺ lymphocyte counts, suggesting improved immune recovery and modulation of host defense against Mycobacterium tuberculosis infection.
Conclusion: AHCC supplementation alongside standard anti-TB therapy improves clinical outcomes and immune responses in patients with pulmonary tuberculosis.
Downloads
References
1. Perhimpunan Dokter Paru Indonesia. Tuberkulosis: Pedoman diagnosis dan penatalaksanaan di Indonesia. 2nd ed. Isbaniah F, Burhan E, Sinaga BYM, Yanifitri DB, Handayani D, Harsini, et al., editors. Jakarta: Perhimpunan Dokter Paru Indonesia; 2021. 1–9 p.
2. Kementerian Kesehatan RI. Pedoman nasional pengendalian tuberkulosis. Indonesia; 2014. p. 1–50.
3. World Health Organization. Global tuberculosis control : Surveillance, planning, financing : WHO report 2005. Geneva: World Health Organization; 2005.
4. Spierings ELH, Fujii H, Sun B, Walshe T. A phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J Nutr Sci Vitaminol (Tokyo). 2007;53(6):536–9.
5. World Health Organization. Global tuberculosis report 2019. Geneva; 2019.
6. Yin Z, Fujii H, Walshe T. Effects of active hexose correlated compound on frequency of CD4+ and CD8+ T cells producing interferon-γ and/or tumor necrosis factor-α in healthy adults. Hum Immunol. 2010;71(12):1187–90.
7. Suknikhom W, Lertkhachonsuk R, Manchana T. The effects of active hexose correlated compound (AHCC) on levels of CD4+ and CD8+ in patients with epithelial ovarian cancer or peritoneal cancer receiving platinum based chemotherapy. Asian Pacific Journal of Cancer Prevention. 2017;18(3):633–8.
8. Sun B, Wakame K, Sato E, Nishioka H, Aruoma OI, Fujii H. The effect of active hexose correlated compound in modulating cytosine arabinoside-induced hair loss, and 6-mercaptopurine- and methotrexate-induced liver injury in rodents. Cancer Epidemiol. 2009;33(3–4):293–9.
9. Terakawa N, Matsui Y, Satoi S, Yanagimoto H, Takahashi K, Yamamoto T, et al. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: A double-blind, placebo-controlled trial. Nutr Cancer. 2008;60(5):643–51.
10. Novak M, Vetvicka V. β-glucans, history, and the present: Immunomodulatory aspects and mechanisms of action. J Immunotoxicol. 2008;5(1):47–57.
11. Novak M, Vetvicka V. Glucans as biological response modifiers. Endocr Metab Immune Disord Drug Targets. 2009;9(1):67–75.
12. Kulkarni AD, Calder P, Ito T. Clinician’s guide to AHCC: Evidence-based nutritional immunotherapy. Kulkarni AD, Calder P, editors. Sapporo: International Congress on Nutrition and Integrative Medicine; 2016.
13. Kenner D. Treatment for immune dysfunction from post-traumatic stress disorder and chronic disease with AHCC. AHCC Published Research. 2011;68–72.
14. Aviles H, O’Donnell P, Orshal J, Fujii H, Sun B, Sonnenfeld G. Active hexose correlated compound activates immune function to decrease bacterial load in a murine model of intramuscular infection. Am J Surg. 2008 Apr;195(4):537–45.
15. Takanari J, Hirayama Y, Homma K, Miura T, Nishioka H, Maeda T. Effects of active hexose correlated compound on the seasonal variations of immune competence in healthy subjects. J Evid Based Complementary Altern Med. 2015;20(1):28–34.
16. Merchand-Reyes G, Santhanam R, Valencia-Pena ML, Kumar K, Mo X, Belay T, et al. Active hexose-correlated compound shows direct and indirect effects against chronic lymphocytic leukemia. Nutrients. 2023;15(24):5138.
17. Cintron SA, Diaz F, Shen Q, Yang FM, Comfort B, Pierce JD. Reducing symptoms and improving physiological functions in patients with post-covid-19 conditions using a mushroom supplement: A pilot study. 2024;4(2):1167.
18. Park EJ, Kim I, Jo EK. Host immune pathways to Mycobacterium tuberculosis infection. J Bacteriol Virol. 2024;54(3):167–90.
19. Yanagimoto H, Satoi S, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, et al. Alleviating effect of active hexose correlated compound (AHCC) on chemotherapy-related adverse events in patients with unresectable pancreatic ductal adenocarcinoma. Nutr Cancer. 2016;68(2):234–40.
20. Gao Y, Zhang D, Sun B, Fujii H, Kosuna KI, Yin Z. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunology, Immunotherapy. 2006;55(10):1258–66.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Jamaluddin Madolangan
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
